Genelux Corp. (GNLX) AI Stock Analysis

• Market Cap: $155.25M
• Dividend Yield: N/A
• Average Volume (3M): 136.87K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.80
• Revenue Growth: -100.00%
• EPS Growth: 11.41%
• Country: US
• Employees: 24
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.20
• Shares Outstanding: 37,773,440
• 10 Day Avg. Volume: 162,187
• 30 Day Avg. Volume: 136,872
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.53
• Enterprise Value/Revenue: 92.23
• Enterprise Value/Gross Profit: -139.12
• Enterprise Value/Ebitda: -2.71
• 1Y Price Target: $18.50
• Price Target Upside: 326.27% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 49 Neutral
• Price Target: $4.00 ▼(-7.83% Downside)

Genelux Corp.'s stock score is primarily impacted by its weak financial performance, characterized by negative profitability and cash flow issues. While technical analysis shows positive momentum, the valuation remains unattractive due to a negative P/E ratio and lack of dividend yield. The absence of earnings call data and corporate events means these factors did not influence the score.

Positive Factors

Innovative Technology

Genelux's proprietary technology platform for oncolytic viral therapies offers a unique approach to cancer treatment, potentially providing a competitive edge in the biopharmaceutical sector by improving patient outcomes and attracting partnerships.

Equity Improvement

The transition to positive stockholders' equity indicates a strengthening balance sheet, which can enhance financial stability and provide a foundation for future growth and investment opportunities.

Partnership Potential

Genelux's strategy to generate revenue through partnerships and collaborations can lead to increased market reach and resource sharing, fostering innovation and potentially accelerating product development and commercialization.

Negative Factors

Negative Profitability

Consistently negative net incomes highlight ongoing operational challenges, which can hinder the company's ability to reinvest in R&D and limit its capacity to achieve sustainable growth without external financing.

High Leverage

High leverage can strain financial flexibility, increasing vulnerability to market volatility and interest rate changes, potentially impacting long-term operational stability and growth prospects.

Negative Cash Flow

Persistent negative cash flow from operations suggests inefficiencies in core business activities, posing risks to liquidity and necessitating reliance on external financing, which may not be sustainable long-term.

Genelux Corp. Business Overview & Revenue Model

Company Description

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

How the Company Makes Money

Genelux Corp. generates revenue primarily through the development and commercialization of its proprietary oncolytic viral therapies. The company may earn income through licensing agreements, collaborations, and partnerships with other pharmaceutical and biotechnology firms that seek to leverage Genelux's technology for the development of new cancer therapies. Additionally, as Genelux progresses in clinical trials and receives regulatory approval for its products, it can generate revenue through the direct sale of its therapeutic solutions to healthcare providers and patients. The company may also benefit from government grants or research funding aimed at advancing cancer treatment technologies.

Genelux Corp. Financial Statement Overview

Summary

Genelux Corp. faces significant financial challenges, with persistent negative profitability and cash flow issues. Despite some improvements in equity, the company remains highly leveraged, and its dependency on financing activities for cash flow sustainability poses risks, especially given the volatile nature of the biotechnology industry.

Income Statement

Genelux Corp. shows weak profitability with consistently negative net incomes over the years. The 2024 revenue growth is misleading due to the low base effect from previous years. Gross profit margin is positive due to costs being reported as negative, but net profit margin remains negative, indicating ongoing operational challenges. Both EBIT and EBITDA margins are negative, underscoring significant profitability issues.

Balance Sheet

The company has improved its equity position, transitioning from negative to positive stockholders' equity in recent years, which is a positive sign. However, the debt-to-equity ratio improved but remains concerning, reflecting high leverage. The equity ratio indicates a low percentage of assets financed by equity, limiting financial flexibility.

Cash Flow

Operating cash flows remain negative, indicating ongoing operational losses. Free cash flow is also negative, with no clear growth trajectory. The operating cash flow to net income ratio is not favorable, reflecting inefficiencies in converting income into cash. Financing activities are primarily sustaining the cash position, which poses risks if external financing becomes unavailable.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	896.00K	8.00K	170.00K	11.07M	0.00	0.00
Gross Profit	-594.00K	8.00K	-848.00K	10.10M	-895.00K	-658.00K
EBITDA	-30.46M	-28.97M	-26.46M	-1.73M	-13.67M	-11.76M
Net Income	-30.39M	-29.87M	-28.30M	-5.21M	-17.80M	-14.86M
Balance Sheet
Total Assets	32.25M	34.72M	27.89M	5.53M	8.13M	14.01M
Cash, Cash Equivalents and Short-Term Investments	27.97M	30.89M	23.19M	397.00K	4.50M	11.35M
Total Debt	1.71M	1.87M	2.52M	26.35M	25.31M	26.06M
Total Liabilities	8.35M	8.44M	8.42M	41.31M	41.24M	36.66M
Stockholders Equity	23.90M	26.27M	19.47M	-35.78M	-33.11M	-22.66M
Cash Flow
Free Cash Flow	-22.81M	-21.61M	-21.30M	-3.62M	-6.58M	-7.22M
Operating Cash Flow	-22.54M	-21.23M	-20.27M	-3.57M	-6.58M	-7.21M
Investing Cash Flow	11.52M	-8.13M	-14.72M	-49.00K	0.00	-20.00K
Financing Cash Flow	9.71M	28.51M	44.02M	-478.00K	-270.00K	18.15M

Genelux Corp. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.34
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GNLX, the sentiment is Positive. The current price of 4.34 is above the 20-day moving average (MA) of 3.74, above the 50-day MA of 3.55, and above the 200-day MA of 3.21, indicating a bullish trend. The MACD of 0.20 indicates Negative momentum. The RSI at 68.11 is Neutral, neither overbought nor oversold. The STOCH value of 84.44 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GNLX.

Genelux Corp. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GNLX	49 Neutral	$155.25M	―	-98.72%	―	-100.00%	11.41%
ORMP	47 Neutral	98.41M	-3.94	0.00%	―	0.00%	-217.26%
ZNTL	46 Neutral	109.65M	-0.67	0.00%	―	-33.76%	17.10%
IMUX	37 Underperform	86.72M	-0.90	0.00%	―	0.00%	35.46%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Genelux Corp. Corporate Events

Genelux Corp. Lowers Stock Option Exercise Prices

On September 1, 2025, Genelux Corporation’s Board of Directors approved a reduction in the exercise prices of certain outstanding stock options under its 2022, 2019, and 2009 Equity Incentive Plans, lowering them to $3.33 per share. This strategic move aims to retain and incentivize employees while preserving cash resources, without causing stock dilution. Additionally, on August 27, 2025, the company held its Annual Meeting of Stockholders, where key decisions included the election of Class III Directors and the ratification of Weinberg & Company, P.A. as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (GNLX) stock is a Buy with a $23.00 price target. To see the full list of analyst forecasts on Genelux Corp. stock, see the GNLX Stock Forecast page.